Experience with registered mucosal vaccines

Vaccine

Volumn 21, Issue 7-8, 2003, Pages 678-683

  Dietrich, Guido ^a   Griot Wenk, Monika ^a   Metcalfe, Ian C ^a   Lang, Alois B ^a   Viret, Jean François ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

Attenuated live vaccines; Mucosal vaccines; Salmonella typhi Ty21a; Vibrio cholerae CVD 103 HgR

Indexed keywords

BACTERIAL VACCINE; CHOLERA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TYPHOID VACCINE; VIRUS VACCINE;

ANTIBODY BLOOD LEVEL; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; CELLULAR IMMUNITY; CHOLERA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; GENE DELETION; GENE INACTIVATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTESTINE EPITHELIUM; LISTERIA MONOCYTOGENES; MICROBIAL ATTENUATION; MUCOSA; MUCOSAL IMMUNITY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SALMONELLA TYPHI; TYPHOID FEVER; VACCINATION; VIBRIO CHOLERAE; VIRUS ATTENUATION; VIRUS INFECTION;

ADMINISTRATION, ORAL; CHOLERA; CHOLERA VACCINES; HUMANS; IMMUNITY, MUCOSAL; MUCOUS MEMBRANE; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINATION; VACCINES, ATTENUATED; VIBRIO CHOLERAE;

EID: 0037472401     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00579-0     Document Type: Conference Paper

References (33)

1. Kaul D., Ogra P.L. Mucosal responses to parenteral and mucosal vaccines. Dev. Biol. Stand. 95:1998;141-146.
2. Neutra M.R., Frey A., Kraehenbuhl J.-P. Epithelial cells: gateways for mucosal infection and immunisation. Cell. 86:1996;345-348.
3. Rescigno M., Urbano M., Valzasina B., Francolini M., Rotta G., Bonasio R.et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2:2001;361-367.
4. Underdown BJ, Mestecky J. Mucosal immunoglobulins. In: Ogra P, Mesteck J, Lamm ME, Strober W, McGhee JR, Bienenstock J, editors. Handbook of mucosal immunology. Boston: Academic Press; 1994. p. 79.
5. Brandtzaeg P. Distribution and characteristics of mucosal immunoglobulin-producing cells. Handbook of immunology. Boston: Academic Press; 1994. p. 251.
6. Mazanec M.B., Nedrud J.G., Kaetzel C.S., Lamm M.E. A three tiered view of the role of IgA in mucosal defence. Immunol. Today. 14:1993;430-435.
7. Oien N.L., Brideau R.J., Walsh E.E., Wathen M.W. Induction of local and systemic immunity against human respiratory syncytial virus using chimeric FG glycoprotein and cholera toxin B subunit. Vaccine. 12:1994;731-735.
8. McDermott M.R., Bienenstock J. Evidence for a common mucosal immunologic system. J. Immunol. 122:1979;1892-1898.
9. Czerkinsky C., Prince S.J., Michalek S.M., Jackson S., Russell M.W., Moldoveanu Z.et al. IgA antibody-producing cells in blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc. Natl. Acad. Sci. U.S.A. 84:1987;2449-2453.
10. Wu H.Y., Russell M.W. Nasal lymphoid tissue. Immunol. Res. 16:1997;187-210.
11. Moldoveanu Z., Russell M.W., Wu H.Y., Huang W.Q., Compans W., Mestecky J. Compartmentalisation within the common mucosal immune system. Adv. Exp. Med. Biol. 371:1995;97-101.
12. Cripps A.W., Kyd J.M., Foxwell A.R. Vaccines and mucosal immunisation. Vaccine. 19:2001;2513-2515.
13. Barnes G.L., Lund J.S., Mitchell S.V., De Bruyn L., Piggford L., Smith A.L.et al. Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine. 20:2002;2950-2956.
14. Kollaritisch H., Cryz S.J. Jr., Lang A.B., Herzog C., Que J.U., Wiedermann G. Local and systemic immune responses to combined Vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunisation and reimmunisation. Vaccine. 18:2000;3031-3039.
15. Viret J.F., Cryz S.J. Jr. Protective immunity induced by typhoid fever and vaccination. Southeast Asian J. Trop. Med. Public Health. 26:1995;150-159.
16. Viret J.F., Favre D., Wegmüller B., Herzog C., Que J.U., Cryz S.J. Jr.et al. Mucosal and systemic immune responses in humans after primary and booster immunisations with orally administered invasive and non-invasive live attenuated bacteria. Infect. Immun. 67:1999;3680-3685.
17. Salerno-Goncalves R., Pasetti M., Sztein M.B. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica Serovar typhi strain Ty21a typhoid vaccine. J. Immunol. 15169(4):2002;2196-2203.
18. Germanier R., Fürer E. Isolation and characterization of galE mutant Ty21a of Salmonella typhi: a candidate strain for a live oral typhoid vaccine. J. Infect. Dis. 141:1975;553-558.
19. Levine M.M., Ferreccio C., Cryz S., Ortiz E. Comparison of enteric coated-capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 336:1990;891-894.
20. Levine M.M., Kaper J.B. Live oral vaccines against cholera: an update. Vaccine. 11:1993;207-212.
21. Nisini R., Biselli R., Matricardi P.M., Fattorossi A., D'Amelio R.D. Clinical and immunologic response to typhoid vaccination in two groups of 30 recruits. Vaccine. 11:1993;582-586.
22. Kantele A., Kantele J.M., Arvilommi H., Mäkelä P.H. Active immunity seen as a reduction in the cell response to oral live vaccine. Vaccine. 9:1991;428-431.
23. Cryz S.J. Jr., Levine M.M., Losonsky G., Kaper J.B., Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect. Immun. 60:1992;3916-3917.
24. Kollaritsch H., Cryz S.J. Jr., Lang A.B., Herzog C., Que J.U., Wiedermann G. Local and systemic immune responses to combined Vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization. Vaccine. 18:2000;3031-3039.
25. Wasserman S.S., Losonsky G.A., Noriega F., Tacket C.O., Castaneda E., Levine M.M. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine. 12:1994;1000-1003.
26. Mollenkopf H., Dietrich G., Kaufmann S.H.E. Intracellular bacteria as targets and carriers for vaccination. Biol. Chem. 382:2001;521-532.
27. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine. 17:1999;S22-S27.
28. Tacket C.O., Losonsky G.A., Nataro J., Cryz S.J., Edelman R., Kaper J.B.et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166:1992;837-841.
29. Tacket C.O., Cohen M.B., Wasserman S.S., Losonsky G., Livio S., Kotloff K.et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect. Immun. 67:1999;6341-6345.
30. Lycke N., Holmgren J. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunisation with cholera toxin. Scand. J. Immunol. 23:1986;611-616.
31. Vajdy M., Lycke N. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunisation. Immunology. 75:1992;488-942.
32. Tacket C.O., Sztein M.B., Losonsky G.A.et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC, aroD and immune response in humans. Infect Immun. 65:1997;452-456.
33. Phalipon A., Sansonetti P. Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery. Biologicals. 23:1995;125-134.